Cargando…

Pyroptosis, a new bridge to tumor immunity

Pyroptosis refers to the process of gasdermin (GSDM)‐mediated programmed cell death (PCD). Our understanding of pyroptosis has expanded beyond cells and is known to involve extracellular responses. Recently, there has been an increasing interest in pyroptosis due to its emerging role in activating t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lisha, Jiang, Mingxia, Qi, Ling, Wu, Yiming, Song, Dongfeng, Gan, Junqing, Li, Yanjing, Bai, Yuxian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486185/
https://www.ncbi.nlm.nih.gov/pubmed/34252266
http://dx.doi.org/10.1111/cas.15059
_version_ 1784577692817948672
author Li, Lisha
Jiang, Mingxia
Qi, Ling
Wu, Yiming
Song, Dongfeng
Gan, Junqing
Li, Yanjing
Bai, Yuxian
author_facet Li, Lisha
Jiang, Mingxia
Qi, Ling
Wu, Yiming
Song, Dongfeng
Gan, Junqing
Li, Yanjing
Bai, Yuxian
author_sort Li, Lisha
collection PubMed
description Pyroptosis refers to the process of gasdermin (GSDM)‐mediated programmed cell death (PCD). Our understanding of pyroptosis has expanded beyond cells and is known to involve extracellular responses. Recently, there has been an increasing interest in pyroptosis due to its emerging role in activating the immune system. In the meantime, pyroptosis‐mediated therapies, which use the immune response to kill cancer cells, have also achieved notable success in a clinical setting. In this review, we discuss that the immune response induced by pyroptosis activation is a double‐edged sword that affects all stages of tumorigenesis. On the one hand, the activation of inflammasome‐mediated pyroptosis and the release of pyroptosis‐produced cytokines alter the immune microenvironment and promote the development of tumors by evading immune surveillance. On the other hand, pyroptosis‐produced cytokines can also collect immune cells and ignite the immune system to improve the efficiency of tumor immunotherapies. Pyroptosis is also related to some immune checkpoints, especially programmed death‐1 (PD‐1) or programmed death‐ ligand 1 (PD‐L1). In this review, we mainly focus on our current understanding of the interplay between the immune system and tumors that process through pyroptosis, and debate their use as potential therapeutic targets.
format Online
Article
Text
id pubmed-8486185
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84861852021-10-07 Pyroptosis, a new bridge to tumor immunity Li, Lisha Jiang, Mingxia Qi, Ling Wu, Yiming Song, Dongfeng Gan, Junqing Li, Yanjing Bai, Yuxian Cancer Sci Review Articles Pyroptosis refers to the process of gasdermin (GSDM)‐mediated programmed cell death (PCD). Our understanding of pyroptosis has expanded beyond cells and is known to involve extracellular responses. Recently, there has been an increasing interest in pyroptosis due to its emerging role in activating the immune system. In the meantime, pyroptosis‐mediated therapies, which use the immune response to kill cancer cells, have also achieved notable success in a clinical setting. In this review, we discuss that the immune response induced by pyroptosis activation is a double‐edged sword that affects all stages of tumorigenesis. On the one hand, the activation of inflammasome‐mediated pyroptosis and the release of pyroptosis‐produced cytokines alter the immune microenvironment and promote the development of tumors by evading immune surveillance. On the other hand, pyroptosis‐produced cytokines can also collect immune cells and ignite the immune system to improve the efficiency of tumor immunotherapies. Pyroptosis is also related to some immune checkpoints, especially programmed death‐1 (PD‐1) or programmed death‐ ligand 1 (PD‐L1). In this review, we mainly focus on our current understanding of the interplay between the immune system and tumors that process through pyroptosis, and debate their use as potential therapeutic targets. John Wiley and Sons Inc. 2021-08-10 2021-10 /pmc/articles/PMC8486185/ /pubmed/34252266 http://dx.doi.org/10.1111/cas.15059 Text en © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review Articles
Li, Lisha
Jiang, Mingxia
Qi, Ling
Wu, Yiming
Song, Dongfeng
Gan, Junqing
Li, Yanjing
Bai, Yuxian
Pyroptosis, a new bridge to tumor immunity
title Pyroptosis, a new bridge to tumor immunity
title_full Pyroptosis, a new bridge to tumor immunity
title_fullStr Pyroptosis, a new bridge to tumor immunity
title_full_unstemmed Pyroptosis, a new bridge to tumor immunity
title_short Pyroptosis, a new bridge to tumor immunity
title_sort pyroptosis, a new bridge to tumor immunity
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486185/
https://www.ncbi.nlm.nih.gov/pubmed/34252266
http://dx.doi.org/10.1111/cas.15059
work_keys_str_mv AT lilisha pyroptosisanewbridgetotumorimmunity
AT jiangmingxia pyroptosisanewbridgetotumorimmunity
AT qiling pyroptosisanewbridgetotumorimmunity
AT wuyiming pyroptosisanewbridgetotumorimmunity
AT songdongfeng pyroptosisanewbridgetotumorimmunity
AT ganjunqing pyroptosisanewbridgetotumorimmunity
AT liyanjing pyroptosisanewbridgetotumorimmunity
AT baiyuxian pyroptosisanewbridgetotumorimmunity